1 November 2018
Felix Swadel
Via email:
[FYI request #8816 email] Dear Felix
REQUEST FOR INFORMATION
Thank you for your request dated 5 October 2018 under the Official Information Act 1982
(OIA). You asked for any data or estimates available relating to the cost of the funded
medicine (emtricitabine with tenofovir disoproxil fumarate) used for pre-exposure prophylaxis
(PrEP). This information is provided in the table below, and covers the period 1 March 2018
to 31 July 2018.
Cost of funded emtricitabine with tenofovir disoproxil fumarate (Truvada) for PrEP
Gross Cost
Number of patients
Emtricitabine with tenofovir disoproxil
$3,416,774.47
818
fumarate (Truvada) for PrEP
Please note that the gross cost refers to the manufacturer’s price, which is the price at which
the supplier supplies a pharmaceutical to the New Zealand market. This does not include
GST and any mark-ups. From 1 March 2018 to 30 June 2018, a confidential rebate applied
to the gross cost of Truvada. From 1 July 2018, the gross cost of Truvada does not include a
confidential rebate. The number of patients refers to the total number of unique patients who
have received funded Truvada for PrEP.
Truvada was
first funded for PrEP from 1 March 2018. You can find the details of the funding
restrictions for PrEP indication
here. Please note that it is also funded for the treatment of
HIV, via endorsement. In instances where a patient has used Truvada for both PrEP and the
treatment of HIV, they are counted under HIV indication (and not PrEP) and excluded from
the table above.
We trust that the provision of this information answers your query, if you have any further
questions please feel free to contact us again.
Yours sincerely
Alison Hill
Director, Engagement and Implementation
A1196751 - qA48037